Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Mechanism-based inhibition of quinone reductase 2 (NQO2): selectivity for NQO2 over NQO1 and structural basis for flavoprotein inhibition.

Dufour M, Yan C, Siegel D, Colucci MA, Jenner M, Oldham NJ, Gomez J, Reigan P, Li Y, De Matteis CI, Ross D, Moody CJ.

Chembiochem. 2011 May 16;12(8):1203-8. doi: 10.1002/cbic.201100085. Epub 2011 Apr 19.

2.

Indolequinone inhibitors of NRH:quinone oxidoreductase 2. Characterization of the mechanism of inhibition in both cell-free and cellular systems.

Yan C, Dufour M, Siegel D, Reigan P, Gomez J, Shieh B, Moody CJ, Ross D.

Biochemistry. 2011 Aug 9;50(31):6678-88. doi: 10.1021/bi2002967. Epub 2011 Jul 19.

3.

Evidence for NQO1 and NQO2 catalyzed reduction of ortho- and para-quinone methides.

Kucera HR, Livingstone M, Moscoso CG, Gaikwad NW.

Free Radic Res. 2013 Dec;47(12):1016-26. doi: 10.3109/10715762.2013.847527. Epub 2013 Oct 25.

PMID:
24074361
4.

The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2).

Winger JA, Hantschel O, Superti-Furga G, Kuriyan J.

BMC Struct Biol. 2009 Feb 24;9:7. doi: 10.1186/1472-6807-9-7.

5.

In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2).

Nolan KA, Caraher MC, Humphries MP, Bettley HA, Bryce RA, Stratford IJ.

Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. doi: 10.1016/j.bmcl.2010.10.070. Epub 2010 Oct 21.

PMID:
21074425
7.

Triazoloacridin-6-ones as novel inhibitors of the quinone oxidoreductases NQO1 and NQO2.

Nolan KA, Humphries MP, Barnes J, Doncaster JR, Caraher MC, Tirelli N, Bryce RA, Whitehead RC, Stratford IJ.

Bioorg Med Chem. 2010 Jan 15;18(2):696-706. doi: 10.1016/j.bmc.2009.11.059. Epub 2009 Dec 21.

PMID:
20036559
8.

Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase.

Wu K, Knox R, Sun XZ, Joseph P, Jaiswal AK, Zhang D, Deng PS, Chen S.

Arch Biochem Biophys. 1997 Nov 15;347(2):221-8.

PMID:
9367528
10.
11.

NRH:quinone oxidoreductase2 (NQO2).

Long DJ 2nd, Jaiswal AK.

Chem Biol Interact. 2000 Dec 1;129(1-2):99-112. Review.

PMID:
11154737
13.

NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs.

Celli CM, Tran N, Knox R, Jaiswal AK.

Biochem Pharmacol. 2006 Jul 28;72(3):366-76. Epub 2006 May 4.

PMID:
16765324
14.

Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches.

Winski SL, Faig M, Bianchet MA, Siegel D, Swann E, Fung K, Duncan MW, Moody CJ, Amzel LM, Ross D.

Biochemistry. 2001 Dec 18;40(50):15135-42.

PMID:
11735396
17.

Evidence for NQO2-mediated reduction of the carcinogenic estrogen ortho-quinones.

Gaikwad NW, Yang L, Rogan EG, Cavalieri EL.

Free Radic Biol Med. 2009 Jan 15;46(2):253-62. doi: 10.1016/j.freeradbiomed.2008.10.029. Epub 2008 Nov 1.

18.

Flavin adenine dinucleotide content of quinone reductase 2: analysis and optimization for structure-function studies.

Leung KK, Litchfield DW, Shilton BH.

Anal Biochem. 2012 Jan 1;420(1):84-9. doi: 10.1016/j.ab.2011.09.011. Epub 2011 Sep 16.

PMID:
21971443
19.
20.

Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2.

Nolan KA, Humphries MP, Bryce RA, Stratford IJ.

Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6. doi: 10.1016/j.bmcl.2010.03.051. Epub 2010 Mar 15.

PMID:
20356739

Supplemental Content

Support Center